A systematic review and economic model of the effectiveness and ...

146
References
307. Findling RL, Short EJ, Manos MJ. Developmental
aspects of psychostimulant treatment in children
and adolescents with attention-deficit/hyperactivity
disorder. J Am Acad Child Adolesc Psychiatry
2001;40:1441–7.
308. Faraone SV, Pliszka SR, Olvera RL, Biederman J.
Adderall and methylphenidate in ADHD. In 2001
Annual Meeting of the American Psychiatric Association,
5–10 May 2001, New Orleans, LA.
309. Faraone SV, Short EJ, Biederman J, Findling RL,
Roe C, Manos MJ. Efficacy of Adderall and
methylphenidate in attention deficit hyperactivity
disorder: a drug–placebo and drug–drug response
curve analysis of a naturalistic study. Int J
Neuropsychopharmacol 2002;5:121–9.
310. Newcorn J, Spencer TJ, Biedermann J, Milton D,
Michelson D. Atomoxetine treatment in children and
adolescents with attention-deficit/hyperactivity disorder
and comorbid oppositional defiant disorder.
Indianapolis, IL: Eli Lilly and Company; 2004.
311. Matza LS, Rentz AM, Secnik K, Swensen AR,
Revicki DA, Michelson D, et al. The link between
health-related quality of life and clinical symptoms
among children with attention-deficit hyperactivity
disorder. J Dev Behav Pediatr 2004;25:166–74.
312. Dunn D, Michelson D, Allen AJ, Kelsey D,
Wernicke JF. Once-daily atomoxetine treatment for
children and adolescents with attentiondeficit/hyperactivity
disorder. Ann Neurol 2002;52
(Suppl 3):S116.
313. Bukstein OG. Once-daily atomoxetine may reduce
attention deficit hyperactivity disorder symptoms
in children and adolescents. Evid Based Ment
Health 2003;6:42.
314. Michelson D. Once-daily administration of
atomoxetine: a new treatment for ADHD. In 155th
Annual Meeting of the American Psychiatric Association,
18–23 May 2002, Philadelphia, PA.
315. Michelson D, Buitelaar J, Danckaerts M,
Gillberg C, Spencer TJ, Zuddas A, et al.
Atomoxetine in the long-term prevention of
relapse in ADHD. Eur Neuropsychopharmacol
2003;13 (Suppl 4):S455–6.
316. Pelham WE, Hoffman MT, Lock T. Evaluation of
once-a-day OROS methylphenidate HCI (MPH)
extended-release tablets versus MPH tid in
children with ADHD in natural school settings.
Pediatr Res 2000;47:31A.
317. Pelham WE, Hoffman MT, Lock T. Evaluation of
once-a-day OROS ® methylphenidate HCl (MPH)
extended-release tablets vs MPH tid in children
with ADHD in a laboratory setting. Pediatr Res
2000;47:180.
318. Connor D. Once a day Concerta methylphenidate
was equivalent to 3 times daily methylphenidate in
children with ADHD. Evid Based Ment Health
2002;5:20.
319. Pliszka SR, Wynne SK, Olvera RL, Browne RG.
Comparing Adderall methylphenidate in
ADHD. In 152nd Annual Meeting of the American
Psychiatric Association, 15–20 May 1999,
Washington, DC.
320. Faraone SV, Pliszka SR, Olvera RL, Skolnik R,
Biederman J. Efficacy of Adderall and
methylphenidate in attention deficit hyperactivity
disorder: a reanalysis using drug–placebo and
drug–drug response curve methodology. J Child
Adolesc Psychopharmacol 2001;11:171–80.
321. Law SF, Schachar RJ. Do typical clinical doses of
methylphenidate cause tics in children treated
for attention-deficit hyperactivity disorder?
J Am Acad Child Adolesc Psychiatry 1999;38:
944–51.
322. Evans SW, Pelham WE, Smith BH, Bukstein O,
Gnagy EM, Greiner AR, et al. Dose-response
effects of methylphenidate on ecologically valid
measures of academic performance and classroom
behavior in adolescents with ADHD. Exp Clin
Psychopharmacol 2001;9:163–75.
323. Smith BH, Pelham WE, Jr., Gnagy E, Molina B,
Evans S. The reliability, validity, and unique
contributions of self-report by adolescents
receiving treatment for attentiondeficit/hyperactivity
disorder. J Consult Clin Psychol
2000;68:489–99.
324. Stein M, Seymour K, Black D, Sarampote C,
Robb A, Conlon C, et al. Effects and side effects of
Concerta methylphenidate (MPH) in children with
ADHD and comorbid internalizing symptoms.
Pediatr Res 2003;53:555A.
325. Wolraich ML. Efficacy and safety of OROS ®
methylphenidate HCl (MPH) extended-release
tablets (CONCERTA), conventional MPH, and
placebo in children with ADHD. Int J
Neuropsychopharmacol 2000;3 (Suppl 1):S329.
326. Wolraich ML, Greenhill LL, Pelham W, Swanson J,
Wilens T, Palumbo D, et al. Randomized,
controlled trial of OROS methylphenidate once a
day in children with attention-deficit/hyperactivity
disorder. Pediatrics 2001;108:883–92.